Novotech

Thank you to all who attended our recent webinar, "Empowering Patients to Overcome Challenges in Orphan Drug Development". This insightful session offered valuable perspectives for stakeholders in the biotech sector, particular those focused on rare disease and orphan drug development. Novotech would like to thank panelists Afshawn C. (Director, Program Management, Avidity Biosciences, Inc.), Michal Meller (Director, Project Management, Novotech), Lauren Dahl (Senior Operations Manager, leapcure), and Ella Balasa (Patient Advocate, Consultant, Balasa Consulting) for their valuable insights into critical strategies for enhancing patient engagement, overcoming operational challenges, and strengthening collaboration between sponsors, CROs, and patient advocacy groups. Thanks also go to Scott Schliebner, VP of Clinical Development Consulting at Novotech for his excellent moderation and for guiding such an informative discussion. If you were unable to attend the on-demand recording is now available for viewing https://lnkd.in/dJ3hiB5s #OrphanDrugs #RareDisease

#DidYouKnow that Cervical Cancer (CC) is the 8th most diagnosed and 9th leading cause of cancer mortality in the world? With over 660,000 new cases and almost 350,000 deaths in 2022, cervical cancer remains a significant global health issue, particularly in regions like Asia and Africa. Early detection, vaccination, and screening remain crucial in curbing these numbers. Since 2019, more than 1,300 clinical trials have been initiated globally, with the Asia-Pacific region leading in trial activity. Novotech’s comprehensive report on Cervical Cancer provides a thorough analysis of the current treatment landscape and research developments in this field, while also highlighting existing and projected trends in funding and research efforts related to Cervical Cancer. Download this free report https://lnkd.in/dRFp8fcp #CervicalCancer #ClinicalTrials #OncologyResearch

Novotech is proud to have been a Featured Sponsor at Outsourcing in Clinical Trials (OCT) Southern California in San Diego last week. A special thank you to everyone who stopped by to connect with our team! Congratulations to Sarah Rose Anderson, our Therapeutic Strategy Director, for her insightful contributions during the panel discussion on "The Clinical Trial Landscape for Small to Mid-Sized Biopharma in Southern California" as well as her own presentation “Do you have the right oncology sites in a competitive market?” The feedback was overwhelmingly positive, with the attendees describing the panel “Wonderfully interactive and insightful.” See you again next year! https://lnkd.in/d-RWTDvD Rod Bugawan, PharmD, Craig Leach #OCT #ClinicalTrials #Novotech

Join us as Peter Legget shares his inspiring journey from CRA to his current role as Clinical Systems Training Lead. Discover how Novotech's commitment to groundbreaking clinical research and positive patient outcomes has fueled Peter's passion for his work. Learn about the memorable moments that have shaped his career, the impact of his contributions, and how Novotech's supportive environment has fostered his professional growth across multiple departments. #lifeatnovotech #novostories #CRA #clinicaltrials

Thank you to everyone who connected with us at RESI Boston 2024! We had many informative discussions with early-stage companies and funding partners regarding how they can collaborate with Novotech to streamline their path to market. If you were not able to connect with Steven Roan, our Director of Business Development, to discuss Novotech’s Equity Funding Model and our expertise in early-phase clinical trials, you can still connect with him here: https://lnkd.in/dTHCWupV We look forward to continuing the conversations and building new partnerships into the future. #RESIBoston #Novotech #Innovation

Novotech would like to thank everyone who joined us at the LSX World Congress USA in Boston on September 11-12! It was a fantastic opportunity to connect with industry leaders from the biotech, medtech, and healthtech sectors and discover the latest innovations and opportunities. A special thanks to those who met with Steven Roan (Associate Business Development Director) and Marina Mullins (Director of Therapeutic Strategy) at the event, to discuss how Novotech can support your clinical trial process, helping to secure funding and bring your innovations to market efficiently and safely. We look forward to continuing these informative conversations and exploring new opportunities together. https://lnkd.in/dJg9sJuG #LSXWorldCongressUSA #ClinicalTrials #Novotech

#Novotech would like to send a big thank you to everyone who attended and engaged with us at the NSW-Greater Bay Area Closed Door Clinical Trial Business Matching 2024 in Guangzhou on 12th September. Shichun Zhang, Novotech’s China BD Director, delivered an insightful presentation titled "Australia’s Role in Early Clinical Trial Development," showcasing Novotech’s unique capabilities in immunotherapy and drug development for Type 2 diabetes and obesity. Through three case studies, Shichun highlighted how Novotech delivers flexible and high-quality #CRO services from early trials through to market. A special thank you to the NSW Government for organizing this meaningful event that brought together key decision-makers from the #pharmaceutical, #biotech and #medtech industries in the Greater Bay Area with potential partner organizations based in Australia. We’re proud to be part of fostering stronger collaboration between Australia and China in clinical trials and innovation. Looking forward to building on the connections made and continuing to deliver exceptional solutions in the clinical trials space. #ClinicalTrials #Partnerships

What an incredible experience at ESMO Congress 2024! From September 13-17, Barcelona was the center of oncology innovation, bringing together global experts to share cutting-edge research and shape the future of cancer care. The congress featured groundbreaking presentations, networking with oncology leaders, and invaluable insights into the latest clinical trials and treatment strategies. At #Novotech, we were proud to contribute to the discussions, drawing from over 27 years of experience in #Oncology and Immuno-Oncology. Our team, including Barry Murphy, Julie Gargano, Mark Anderson, Beata Żukowska, and Diana Gheorghi (Filipescu), connected with biotech partners, Key Opinion Leaders, and industry innovators, sparking ideas that will drive future the development of many new and innovative therapies to help improve outcomes for patients of many different types of cancers. We’d like to extend a warm thank you to everyone who met with us at this incredible event. Together, we can continue to push the boundaries of cancer research and work towards a healthier future. We hope to keep in touch with everyone, and Look forward to more collaboration and innovation in the future. https://lnkd.in/dJC9JA7r #ESMO2024 #CancerResearch #ClinicalTrials

A big thank you to everyone who visited us at BIOHK 2024! It was a fantastic opportunity to connect with industry leaders, innovators, and investors from around the world. We are thrilled to have been a part of such a dynamic event bridging the biotech communities of East and West. A special thanks to Chris Chong, Ada Ip and Rachel Wang for representing Novotech and engaging in insightful discussions at the event. We hope visitors to the event enjoyed learning more about how Novotech supports biotech and pharmaceutical clients throughout the clinical trial process from lab to launch. We look forward to continuing the conversations and partnerships started at BIOHK, and helping new partners bring their innovative products to market. https://lnkd.in/dMYKB4-B #BIOHK2024 #ClinicalTrials #Novotech

The 25th Annual CABS 2024 BioPacific Conference in San Francisco was a resounding success, and Novotech would like to thank those that took the time to meet with us. It was a pleasure connecting and catching up with industry leaders and exploring new opportunities in the #biopharmaceutical space across the Pacific Rim. Special thanks to Angela Wang, our China Commercial Director, for sharing valuable insights during the Lunch & Learn session on the “Evolving Biotech Landscape: Funding, Talent & Trials.” We look forward to continuing the conversations and partnerships formed during this incredible event! https://lnkd.in/dzmbDG9U #Novotech #CABS2024 #BioPacificConference